Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis

References

• Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1340.
   PubMed Web of Science ®Google Scholar
• Violi F, Basili S, Berger J, et al. Anti-platelet therapy in peripheral artery disease. In: Gresele P, Born GVR, Patrono C, et al., editors. Antiplatelet agents: handbook of experimental pharmacology. Berlin: Springer-Verlag; 2012. p. 547–563.
   Google Scholar
• Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328–333.
   PubMed Web of Science ®Google Scholar
• Katwal AB, Dokun AO. Peripheral arterial disease in diabetes: is there a role for genetics? Curr Diab Rep. 2011 Jun;11(3):218–225.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688–699.
   PubMed Web of Science ®Google Scholar
• Eagle KA, Hirsch AT, Califf RM, et al. REACH registry investigators. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the United States: insights from the REACH registry. Crit Pathways Cardiol. 2009;8:91–97.
   PubMedGoogle Scholar
• Mahoney EM, Wang K, Keo HH, et al. REACH registry investigators. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010;3(6):642–651.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Tan MK, Lin PJ, et al. Vascular protection registry; guideline oriented approach in lipid lowering registry investigators. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. J Vasc Surg. 2006 Oct;44(4):776–781.
   PubMed Web of Science ®Google Scholar
• Diehm C, Allenberg JR, Pittrow D, et al. German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–2061.
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Cohen DJ, et al. REACH registry investigators. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38–45.
   PubMed Web of Science ®Google Scholar
• Margolis J, Barron JJ, Grochulski WD. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm. 2005;11(9):727–734.
   PubMedGoogle Scholar
• Krempf M, Parhofer KG, Steg PG, et al. Reach registry investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010;105(5):667–671.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. The next 10 years in the management of peripheral artery disease: perspectives from the ‘PAD 2009’ Conference. Eur J Vasc Endovasc Surg. 2010 Sep;40(3):375–380.
   PubMed Web of Science ®Google Scholar
• Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Hartman L, Town RJ, et al. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13:209–215.
   PubMed Web of Science ®Google Scholar
• Malyar N, Furstenberg T, Wellmann J, et al. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J. 2013;34(34):2706–2714.
   PubMed Web of Science ®Google Scholar
• Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012 Sep 11;126(11):1345–1354.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Apr 2;127(13):1425–1443.
   PubMed Web of Science ®Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery.2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020–2045.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127(14):1522–1526.
   PubMed Web of Science ®Google Scholar
• Cambou JP, Aboyans V, Constans J, et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART registry. Eur J Vasc Endovasc Surg. 2010;39(5):577–585.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al. Prevention of progression of arterial disease and diabetes study group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Price JF, Stewart MC, et al Aspirin for asymptomatic atherosclerosis trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.
   PubMed Web of Science ®Google Scholar
• Azarbal A, Clavijo L, Gaglia MA Jr. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. 2015;20(2):144–156.
   PubMed Web of Science ®Google Scholar
• Inglis SC1, Bebchuk J, Al-Suhaim SA, et al. Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. Int J Cardiol. 2013 Sep 30;168(2):1094–1101.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014 Apr 10;3(2):e000697.
   PubMed Web of Science ®Google Scholar
• Hoeks SE, Scholte Op Reimer WJM, Van Gestel YRBM, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2:338–343.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med. 2002;17:895–904.
   PubMed Web of Science ®Google Scholar
• Al-Omran M. Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vasc Health Risk Manag. 2007;3:1019–1027.
   PubMedGoogle Scholar